InnoCare Advances Mesutoclax Into Head-to-Head Phase III AML Trial In China

InnoCare Pharma said China’s Center for Drug Evaluation approved a registrational Phase III study of its BCL2 inhibitor Mesutoclax plus Azacitidine versus Venetoclax plus Azacitidine in elderly or unfit patients. The approval advances the registrational path for Mesutoclax, which is a positive clinical/regulatory milestone though details on efficacy outcomes were not provided.

Analysis

InnoCare Pharma said China’s Center for Drug Evaluation approved a registrational Phase III study of its BCL2 inhibitor Mesutoclax plus Azacitidine versus Venetoclax plus Azacitidine in elderly or unfit patients. The approval advances the registrational path for Mesutoclax, which is a positive clinical/regulatory milestone though details on efficacy outcomes were not provided.